[PDF] Top 20 Pensamiento social sueco sobre América Latina

... of ivabradine in the therapeutic armamentarium must be ...lowering, ivabradine is probably suitable for most patients with SAP and is of particular interest in patients in whom beta blockers should ... See full document

... of ivabradine, a drug that selectively reduces heart rate for the treatment of stable angina pectoris in different clinical condi- tions, including patients with preserved or impaired left ventricular (LV) ... See full document

... Abstract: Ivabradine is a selective antagonist of the funny channels with anti-anginal and anti- ischemic properties, approved for the treatment of coronary artery disease (CAD) and heart failure ...of ... See full document

... 4. Coronary sinus reducer stenting: In the setting of coronary arteries obstruction, in- creased coronary sinus (CS) pressure can re- duce myocardial ischemia by redistribution of collateral blood flow from nonischemic ... See full document

... Evidence review: There are now convincing data from phase II and multicenter phase III randomized, double-blind, placebo-controlled trials that methylnaltrexone induces laxation in patients with long-term opioid ... See full document

... Evidence review: In clinical trials, including phase III studies, superior efficacy compared to placebo and good efficacy compared to standard antidepressants was shown for agomelatine[r] ... See full document

... alternative therapeutic options are extremely limited, and the onset of imatinib resistance is usually associated with disease progression and worsening ...Preliminary evidence from the initial phase I dose ... See full document

... Until February 2009, there were few tenable therapeutic alternatives for gout, and no new drug for its management had been approved in the US since allopurinol in 1964. Uricosuric drugs are of limited ... See full document

... Introduction: Thyroid cancer is a rare disease with an incidence of around 37,000 cases per year. However, its incidence is rising faster than many other cancers and for men this disease ranks highest overall in ... See full document

... Introduction: The available treatment options for euvolemic and hypervolemic hyponatremia are limited, and consist mainly of fluid restriction, diuresis, or hypertonic solutions. Most of these therapies are neither well ... See full document

... line therapy in patients with tumor translocation sarcomas. Trabectedin is currently not commercially available in the United States and Canada. It is currently available in several expanded access studies focusing on ... See full document

... but its use has been limited by the development of tachyphylaxis, nitrate tolerance, and ...conflicting evidence regarding its long-term safety profile and potential to worsen renal function ... See full document

... for its specificity and high affinity for renin thereby minimizing its potential to act at alternative sites and theoretically minimizing potential adverse ... See full document

... not impact adversely on another parameter ...that its insulin-sensitizing and lipid normalization properties have to be at least equivalent to those associated with PPAR gamma or PPAR-alfa/gamma agonists ... See full document

... Abstract: Oral anticoagulant therapy for stroke prevention in atrial fi brillation patients has been remarkably changed by the introduction of non-vitamin k oral anticoagulants (NOAC). Apixaban was the third NOAC ... See full document

... little evidence regarding whether nintedanib and pirfenidone are beneficial in patients with more advanced IPF who were excluded from the pivotal trials; the drugs show long-term efficacy, and the drugs were ... See full document

... established its place in therapy in highly emetogenic regimens, as it has been integrated into the practice guidelines of ASCO, ESMO, MASCC, and NCCN (Table ...The evidence for its utility in ... See full document

... Maraviroc is in the late stages of clinical development. Data from phase II/III studies determining its virologic effect compared with existing regimens are not yet available. However, it is likely that maraviroc ... See full document

... overrepresentation of these mutations in the study cohort may artificially improve OS compared to historical controls. However, as EGFRvIII is rarely expressed in secondary GBMs, the effect of IDH1/2 mutations is likely ... See full document

... The study is aimed to assess the patient knowledge with the help of knowledge assessment questionnaire (KAQ) about the disease and to evaluate the importance of education as an instrument of therapy in controlling the ... See full document